Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure

https://doi.org/10.1016/0002-9343(86)90148-8Get rights and content

Abstract

The available data indicate that the beta-adrenergic receptors that mediate positive inotropic responses undergo “down-regulation,” a cellularly mediated decrease in surface receptor number, in congestive heart failure. This decrease in beta-adrenergic receptor number is proportional to the degree of myocardial dysfunction and the loss of contractility that occurs in congestive heart failure. It appears to be chamber-specific, occurring to the greatest degree in the most severely affected ventricular chamber, and is specific to the beta-adrenergic receptor subtype. Beta-adrenergic receptor down-regulation may be the result of the excessively high levels of plasma catecholamines seen in congestive heart failure, inasmuch as a similar phenomenon of beta-adrenergic receptor down-regulation is seen in animals treated with high doses of catecholamines. The specific down-regulation in cardiac beta receptors may be, in part, the cause of the decrease in myocardial function observed during long-term beta-adrenergic receptor stimulation, and an actual decrease in beta-adrenergic receptor number has been observed in myocardial tissue from patients with congestive heart failure. Down-regulation of beta receptors in congestive heart failure results in a decrease or loss of efficacy of beta-adrenergic receptor agonists on long-term administration. This is especially evident for partial agonists, which are more dependent on receptor number for their positive inotropic effects than full agonists. Although beta receptors are down-regulated in congestive heart failure, myocardial alpha1-adrenergic receptors and histamine H2 receptors do not appear to be subject to this same regulatory process. Inasmuch as stimulation of both of these receptors results in a positive inotropic effect, further study should be given to the potential therapeutic utility of selective stimulation of myocardial alpha1-adrenergic receptors and histamine H2 receptors in congestive heart failure. It is evident that the status of specific receptor subtypes in pathophysiologic states such as congestive heart failure must be considered when assessing the likelihood of success in treating patients with beta-adrenergic receptor agonists.

References (54)

  • MM Applefeld et al.

    Intermittent continuous outpatient dobutamine infusion in the management of congestive heart failure

    Am J Cardiol

    (1983)
  • HJ Schumann et al.

    Alpha-adrenoceptors in the ventricular myocardium: clonidine, naphazoline and methoxamine as partial alpha agonists exerting a competitive dualism in action to phenylephrine

    Eur J Pharmacol

    (1976)
  • RR Ruffolo et al.

    Systemic hemodynamic effects of dopamine, (±)-dobutamine and (+)- and (-)-enantiomers of dobutamine in anesthetized normotensive rats

    Eur J Pharmacol

    (1985)
  • G Baumann et al.

    Possible value of H2-receptor agonists for treatment of catecholamine-insensitive congestive heart failure

    Pharmac Ther

    (1984)
  • WS Colucci et al.

    Decreased lymphocyte beta-adrenergic receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol

    N Engl J Med

    (1981)
  • MR Bristow et al.

    Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts

    N Engl J Med

    (1982)
  • MR Bristow et al.

    Beta-adrenergic receptor measurements in normal and failing human right and left ventricle

    Circulation

    (1982)
  • MR Bristow et al.

    Selective down-regulation of beta1-adrenergic receptors in the failing human heart

    Circulation

    (1984)
  • JA Laser et al.

    Beta-adrenergic receptor binding in human endomyocardial biopsy tissue

    JACC

    (1984)
  • G Baumann et al.

    Effects of the H2-receptor agonist impromidine in human myocardium from patients with heart failure due to mitral and aortic valve disease

    J Cardiovasc Pharmacol

    (1983)
  • R Ginsburg et al.

    Myocardial performance and extracellular ionized calcium in a severely failing human heart

    Ann Intern Med

    (1983)
  • MB Fowler et al.

    Impaired beta-adrenergic inotropic response in severe heart failure

    Circulation

    (1984)
  • A Hedberg et al.

    Regulation of beta1- and beta2-adrenergic receptors in human atria

    Circulation

    (1983)
  • R Ginsburg et al.

    Beta2-receptors are coupled to muscle contraction in human ventricular myocardium

    Circulation

    (1984)
  • EJ Ariens

    The classification of beta-adrenoceptors

    Trends Pharmacol Sci

    (1981)
  • JA Thomas et al.

    Beta receptor desensitization in lympho-cytes from patients with congestive heart failure

    Pharmacologist

    (1977)
  • EP Gordon et al.

    Correlation between beta-adrenergic receptors in human lymphocytes and heart

    Circulation

    (1983)
  • Cited by (32)

    • Heart failure and its treatment from the perspective of sympathetic nerve activity

      2022, Journal of Cardiology
      Citation Excerpt :

      However, adrenaline did not increase plasma noradrenaline levels in the rabbits with heart failure induced by doxorubicin both in the anesthetized rabbits and the pithed rabbits with stimulated sympathetic outflow [24]. These findings suggest that presynaptic β-receptors may be down-regulated by the elevated plasma noradrenaline caused by heart failure, which is consistent with a study that reported that β-receptors were down regulated in heart failure [25]. Thus, involvement of presynaptic β-receptors in noradrenaline release may be different according to the severity of heart failure.

    • Cardiac vagal control in a knock-in mouse model of dilated cardiomyopathy with a troponin mutation

      2017, Autonomic Neuroscience: Basic and Clinical
      Citation Excerpt :

      Therefore, we cannot rule out the possibility that peripheral, as well as central impairment also might contribute to the reduction of cardiac vagal activity in more advanced stages of congestive heart failure in our DCM mouse model. Although others have frequently reported downregulation of adrenergic signaling and postsynaptic dysfunction in sympathetic regulation of the heart in heart failure (Ruffolo and Kopia, 1986; Vatner et al., 1999), our data suggested that vagal postsynaptic function was preserved in the DCM mouse. Electrical stimulation of cervical vagal nerve at both 5 and 10 Hz increased cardiac interval and myocardial interstitial ACh level in WT mice as well as in DCM mice, and there were no differences in these responses between WT and DCM mice (Figs. 1 and 3).

    • Neonatal Blood Pressure Support: The Use of Inotropes, Lusitropes, and Other Vasopressor Agents

      2012, Clinics in Perinatology
      Citation Excerpt :

      Therefore, in neonates with escalating dopamine infusion, the pattern of receptor stimulation is first dopaminergic, then α-adrenergic, and finally β-adrenergic (Fig. 3).3,4,28 Of note is that the hemodynamic effects and the clinical response to dopamine (and other vasopressors and inotropes) is altered by downregulation of adrenergic receptors caused by the critical illness–associated prolonged endogenous and the treatment-associated exogenous receptor stimulation.27 Furthermore, because cardiovascular adrenergic receptor expression is regulated by corticosteroids,26 the documented higher incidence of relative adrenal insufficiency29 also contributes to the observed attenuated hemodynamic response and the development of vasopressor-dependence in preterm and term neonates.

    • Reduction of vasopressor requirement by hydrocortisone administration in a patient with cerebral vasospasm

      2001, British Journal of Anaesthesia
      Citation Excerpt :

      In animal studies, adrenoceptor down-regulation and decreased responsiveness occur when catecholamines are given in large doses and/or for long periods.7–9 Similar findings occur in human subjects.10–12 In this report, phenylephrine was infused for three days before a progressive increase in dose requirement, to achieve the same target blood pressure, was observed (Fig.1).

    View all citing articles on Scopus
    View full text